These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22315148)

  • 1. Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres.
    Harrison-Woolrych M; Härmark L; Tan M; Maggo S; van Grootheest K
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1065-72. PubMed ID: 22315148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Maggo S; Tan M; Savage R; Ashton J
    Drug Saf; 2012 Jan; 35(1):33-43. PubMed ID: 22149418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand.
    Harrison-Woolrych M; Ashton J
    Drug Saf; 2011 Sep; 34(9):763-72. PubMed ID: 21830838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Varenicline and abnormal sleep related events.
    Savage RL; Zekarias A; Caduff-Janosa P
    Sleep; 2015 May; 38(5):833-7. PubMed ID: 25409105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do package inserts reflect symptoms experienced in practice?: assessment using an automated phone pharmacovigilance system with varenicline and zolpidem in a primary care setting.
    Haas JS; Amato M; Marinacci L; Orav EJ; Schiff GD; Bates DW
    Drug Saf; 2012 Aug; 35(8):623-8. PubMed ID: 22764754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memory impairment associated with varenicline: a case series from the New Zealand Intensive Medicines Monitoring Programme.
    Tan M; Harrison-Woolrych M
    Eur J Clin Pharmacol; 2013 May; 69(5):1195-6. PubMed ID: 23232978
    [No Abstract]   [Full Text] [Related]  

  • 7. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric adverse events of varenicline: a systematic review of published reports.
    Ahmed AI; Ali AN; Kramers C; Härmark LV; Burger DM; Verhoeven WM
    J Clin Psychopharmacol; 2013 Feb; 33(1):55-62. PubMed ID: 23277249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand.
    Harrison-Woolrych M; Ashton J
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):949-53. PubMed ID: 20602347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey.
    Enger C; Younus M; Petronis KR; Mo J; Gately R; Seeger JD
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):705-15. PubMed ID: 23349095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.
    Nahvi S; Wu B; Richter KP; Bernstein SL; Arnsten JH
    Drug Alcohol Depend; 2013 Sep; 132(1-2):47-52. PubMed ID: 23332438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New reports examine psychiatric risks of varenicline for smoking cessation.
    Kuehn BM
    JAMA; 2012 Jan; 307(2):129-30. PubMed ID: 22235073
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of adverse cardiovascular events from varenicline balanced against the benefits in mortality from smoking cessation.
    Kistler CE; Goldstein AO
    Nicotine Tob Res; 2012 Dec; 14(12):1391-3. PubMed ID: 22422928
    [No Abstract]   [Full Text] [Related]  

  • 18. Does varenicline worsen psychiatric symptoms in patients with schizophrenia or schizoaffective disorder? A review of published studies.
    Cerimele JM; Durango A
    J Clin Psychiatry; 2012 Aug; 73(8):e1039-47. PubMed ID: 22967780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varenicline: aggression and homicidal ideation.
    Prescrire Int; 2012 Feb; 21(124):42-3. PubMed ID: 22413719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.